Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy-Reference-Cited by-同舟云学术

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy

Published:2020-11-06 Issue:2 Volume:11 Page:384-407
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Iyer Sonia^ORCID,Zhang Shuang,Yucel Simge,Horn Heiko^ORCID,Smith Sean G.,Reinhardt Ferenc,Hoefsmit Esmee,Assatova Bimarzhan^ORCID,Casado Julia^ORCID,Meinsohn Marie-Charlotte,Barrasa M. Inmaculada,Bell George W.^ORCID,Pérez-Villatoro Fernando^ORCID,Huhtinen Kaisa^ORCID,Hynninen Johanna^ORCID,Oikkonen Jaana^ORCID,Galhenage Pamoda M.,Pathania Shailja,Hammond Paula T.,Neel Benjamin G.,Farkkila Anniina^ORCID,Pépin David,Weinberg Robert A.^ORCID

Funder

NIH

Ovarian Cancer Research Program

US Army Medical Research

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activin A-Targeted Therapy in Cancer: An Updated Review on Challenges and Opportunities in Clinical Translation;Current Pharmaceutical Design;2024-08-27

2. High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils;2024-08-07

3. Localizedin vivoprodrug activation using radionuclides;2024-08-06

4. The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions;The Journal of Pathology;2024-07-02

5. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8⁺TILs based onBRCA1/2mutation status in epithelial ovarian cancers;Journal for ImmunoTherapy of Cancer;2024-07